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Impact of Polypharmacy on Adherence to Evidence-based Medications in
Patients who Underwent Percutenous Coronary Intervention
Shaban Mohammed, Abdulrahaman Arabi, Ayman El-Menyar, Sabir Abdulkarim,
Ahmed Awaisu1, Awad Alqahtani, Khalid Al Siyabi, Tarek Aboughazala, Salah Arafa,
Amina Sadiq, Rajvir Singh, Jassim Al suwaidi
Heart Hospital, Hamad Medical Corporation, Doha, Qatar, 1College of Pharmacy,
Qatar university, Doha, Qatar
Background: The study primary aims to evaluate the impact of polypharmacy on
adherence to evidence-based medications (EBM) among patients who underwent
percutaneous coronary intervention (PCI) in Qatar.
Methods: We conducted a retrospective analysis for patients who underwent PCI at a
tertiary cardiac care hospital in Qatar. Patients who had polypharmacy (deﬁned as 6
medication or more) were compared with those who had no polypharmacy at hospital
discharge in term of adherence to dual antiplatelet therapy (DAP), beta-blocker (BB),
angiotensin converting enzyme inhibitors (ACEI), and statin used. Data were analyzed
and compared using Chi-square and student T test. Outcome was the adherence to the
ﬁrst reﬁll EBM.
Results: A total of 557 patients (85% male) who underwent PCI were included. The
mean age of the study population was 53.
Conclusion: In patients underwent PCI, polypharmacy at discharge could play a
negative role in the adherence to the ﬁrst reﬁll evidence based medications. Further
studies should investigate other parameters that contribute to long term non-adherence.
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High Dose Atorvastatin Improved Endothelial Progenitor Cells Mobilization in
Patients with Non-ST Elevated Acute Coronary Syndrome
Biao Xu, Jiaxin Ye, Jun Xie
Nanjing Gulou Hospital, Nanjing, China
Background: High dose statin can signiﬁcantly decrease the risk of recurrent major
cardiac events in patients with acute coronary syndromes (ACS), but the mechanisms
are still unclear. We hypothesized that the protective effect of high dose statin in ACS
worked through profoundly increasing EPCs mobilization and subsequent myocardial
neovascularization. Thereby we study the effects of high dose atorvastatin on EPCs
mobilization in patients, then in order to investigate the possible mechanism under-
lying the EPCs mobilization effects of high dose statins in mouse myocardial
infarction model, and thereby high dose statins exert beneﬁcial effects on myocardial
neovascularization, left ventricular function and remodeling.
Methods: From December 2010 to July 2011, patients with NSTEACS (n¼48)
scheduled for percutaneous coronary intervention were randomly given a standard
(20mg/d) or high dose atorvastatin (80mg/QN*2 days, then 40mg/QN*28 days) at
admission. Early human EPCs deﬁned as CD45low/-CD34+KDR+CD133+ cells were
dynamically counted by ﬂow cytometry. Cardiovascular evidences were follow-
upped. In addition to clinical trial, Wild-type C57BL /6 mice with acute anterior
myocardial infarction (AMI) were randomized to receive vehicle as control, or stan-
dard or high dose atorvastatin (high 15 mg/kg*day, standard 5 mg/kg*day) for 4
weeks by gavage after AMI. Early mouse EPCs deﬁned as c-Kit+FLK-1+Sca-1+ cells
were count by ﬂow cytometry. The plasma levels of vascular endothelial growth factor
(VEGF) and stromal cell-derived growth factor-1 (SDF-1) were determined by ELISA
both in patients and animal subjects. Phosphorylation of Akt/ protein kinase B (PKB)
and endothelial nitric oxide synthase (eNOS) in mouse bone marrow were assessed by
Western blotting analysis.
Results: Patients the enhanced mobilization of EPCs and increased plasma
VEGF levels in high dose atorvastatin were observed before PCI (P<0.01), while the
level of early EPCs and the levels of VEGF kept still in standard group. After the PCI,
the early EPCs in both two groups went up (P<0.05), but the level of early EPCs and
VEGF in high dose group was still higher than the standard group (P<0.01). And
there was a signiﬁcant positive relationship between the level of EPCs and VEGF at
day 2 (r¼0.77, P<0.01). And there were no different among the levels of SDF-1 and
hsCRP in these two groups at each time point (P>0.05).
Mice the same effect of high dose atorvastatin on EPC mobilization was observed in
animal models (all P<0.01). Under high dose atorvastatin treatment, left ventricular
dysfunction and interstitial ﬁbrosis were markedly improved in AMI mice (P<0.05).
Furthermore, the levels of phospho-Akt and phospho-eNOS were up-regulated in the
bone marrow of AMI mice (P<0.01).
Conclusion: Our ﬁndings suggested high dose atorvastatin enhanced the EPCs
mobilization in both NSTEACS patients and AMI mice. These effects may be
mediated through an increase in the plasma VEGF level as well as activation of PI-3K/
Akt/eNOS signaling pathway in bone marrow.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORATCTAP A-008
Preventive Versus Culprit-only Percutaneous Coronary Intervention in ST-
elevation Myocardial Infarction Patients with Multivessel Disease: A Meta-
Analysis
Yeo-Jeong Song, Jae-Sik Jang, Joo-Il Yang, Ho-Young Lee, Han-Young Jin,
Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim
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Background: Only culprit vessel is proposed to be treated during primary percuta-
neous coronary intervention (PCI) in ST-segment elevation myocardial infarction
(STEMI) patients with multivessel coronary artery disease. However, the beneﬁts of
complete revascularization in patients with STEMI are still controversial.
Methods: Relevant studies published through September 2013 were searched and
identiﬁed in the electronic databases. Primary endpoint was all-cause mortality at the
longest follow-up. Secondary endpoints included myocardial infarction (MI), repeat
revascularization, and major adverse cardiac events (MACE). Summary estimates
were obtained using a random-effects model.
Results: From 836 initial citations, 5 randomized trials and 24 observational
studies with 43,960 patients (7,937 preventive and 36,023 culprit-only) were
included in this study. There were no signiﬁcant differences in all-cause mortality
(odds ratios [OR] 1.01, 95% CI 0.77 to 1.32; p <0.001), MI (OR 1.12, 95% CI
0.63 to 1.99, p ¼ 0.70), and repeat revascularization (OR 0.72, 95% CI 0.51 to
1.02; p ¼ 0.07) between the two groups. Comparison of preventive PCI versus
culprit-only PCI group disclosed ORs for MACE of 0.83 (95% CI 0.59 to 1.18; p
¼ 0.31). Sensitivity analysis suggested lower odds of repeat revascularization (OR
0.37, 95% CI 0.26 to 0.54; p<0.001) and MACE (OR 0.64, 95% CI 0.43 to 0.94; p
¼ 0.02) with preventive PCI in randomized trials compared with those in non-
randomized studies. However, stratiﬁed analysis according to the different strategy
demonstrated a signiﬁcantly lower incidence of all-cause mortality with staged PCI
compared with culprit-only or multivessel PCI during the index procedure
(Figure).
Conclusion: Current analysis of heterogeneous studies did not reveal any beneﬁt of
multivessel PCI over culprit-only PCI during index procedure or staged PCI in pa-
tients with STEMI. Further study is needed to clarify which PCI strategies will have
greater beneﬁt.TCTAP A-009
The Efﬁcacy of Everolimus-eluting Stent (EES) Implantation in Patients with
ST-elevation Myocardial Infarction: Outcomes of 2-year Clinical Follow-up
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Background: Drug-eluting stents (DES) are increasingly used for treatment of acute
coronary syndrome (ACS), but there are few comparisons of outcomes of secondL/Acute Coronary Syndrome: STEMI, NSTE-ACS S3
